Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Mohamad Mohty, Myriam Labopin et al.|Bone Marrow Transplantation|2022Cited by 20
Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized TrialMartin Bornhaeuser, Christian Thiede, Johannes Schetelig et al.|Blood|2008Cited by 1
MRD Status Impact on Secondary Acute Myeloid Leukemia Outcomes after Allogeneic Hematopoietic Cell Transplantation. A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Arnon Nagler, Myriam Labopin et al.|Transplantation and Cellular Therapy|2021Cited by 0